Optimal Asthma Control: Time for a New Target

The stepwise approach to pharmacological treatment in adult asthma mandates that asthma treatment is progressively stepped up to achieve symptom control and reduce the risk of exacerbations, and stepped down after a period of prolonged control. This review proposes that in adults without good asthma...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2020-06, Vol.201 (12), p.1480-1487
Main Authors: Beasley, Richard, Braithwaite, Irene, Semprini, Alex, Kearns, Ciléin, Weatherall, Mark, Pavord, Ian D
Format: Article
Language:English
Subjects:
Airway management
Asthma
Chronic obstructive pulmonary disease
Medical treatment
Respiratory diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The stepwise approach to pharmacological treatment in adult asthma mandates that asthma treatment is progressively stepped up to achieve symptom control and reduce the risk of exacerbations, and stepped down after a period of prolonged control. This review proposes that in adults without good asthma control, 'well-controlled' asthma can only be achieved in around 70% of patients across the strata of severity, and only if there is a progressive increase in ICS/LABA therapy to a maintenance ICS dose which causes the same magnitude of systemic side effects as oral prednisone at a 5mg daily dose. Another consideration is that in a person with asthma, there are numerous overlapping disorders that can present with symptoms indistinguishable from asthma, comorbidities that contribute to poor control and lifestyle/environmental factors that require treatment in their own right, and that if specifically managed might lead to better outcomes. The disparity between patients' perceptions and guideline assessment of control may be due to 'partially controlled' asthma being associated with near maximal levels of quality of life, with minimal impairment. Finally it is widely assumed that asthma symptom control equates to elimination of risk of asthma attacks, an assumption that may not apply to many patients, particularly those with more severe asthma. We propose that further research is undertaken to determine the optimal levels of asthma control, and the potential value of different treatment targets such as control of type-2 airway inflammation, that can be achieved with currently available treatment, based on efficacy, side effects and cost.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201910-1934CI